← All Glaukos CORP filings

Glaukos CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
GKOS
Glaukos CORP
10-K: Glaukos Corporation Reports Strong 2024 Results Driven by iDose TR Launch and Global Expansion
Glaukos Corporation's 2024 10-K filing reveals a year of significant growth, highlighted by the commercial launch of iDose TR and expansion in both U.S. and international markets.
NYSE
GKOS
Glaukos CORP
10-K: Glaukos Corp. Files 10-K Report: iDose TR Approval, Financial Performance, and Future Outlook
Glaukos Corporation's 10-K filing highlights the FDA approval of iDose TR, its financial performance, and strategic initiatives for growth in glaucoma, corneal, and retinal treatments.